Lupin's Q2 FY27 Results Show 22% Decline in Net Profit

Lupin reported a sharp 22.2% drop in net profit to Rs 1,155.3 crore in Q2 FY27 from Rs 1,484.8 crore a year earlier, even as revenue from operations climbed 11.1% to Rs 7,827.3 crore.

The numbers highlight clear pressure on profitability despite steady business expansion across key markets.

Rising operating expenses and an exceptional antitrust settlement weighed heavily on the bottom line.

Investors now ask whether these costs and one-time charges are overshadowing the company’s solid topline momentum and underlying growth. The quarter underscores the challenge of converting strong sales growth into sustained earnings gains as cost pressures continue to test Lupin’s profitability.

Lupin Q2 FY27 Results Show a Revenue-Profit Disconnect

Sales rose 14% to Rs 7,785.5 crore, yet EBITDA fell 10.7% to Rs 2,171.2 crore. The EBITDA margin contracted sharply from 35.6% to 27.9%.

• Employee costs jumped 28.8%.
• Manufacturing and other expenses climbed 23.2%.

Operating expenses grew faster than sales, squeezing margins and preventing revenue gains from flowing through to higher earnings. This gap between topline expansion and bottom-line performance defines the quarter’s mixed outcome.

Also Read: India's Drug Pricing Architecture: Why the Rules Keep Expanding

Exceptional Settlement Adds to Lupin’s Profit Decline

Lupin’s US subsidiary settled an antitrust matter for Rs 316.28 crore without any admission of liability or wrongdoing. The company continues to carry provisions for potential future settlements in similar cases.

This exceptional charge directly reduced reported net profit. Investors should separate such one-time items from core operating performance when assessing the quarter. The settlement explains a meaningful portion of the earnings decline beyond the impact of higher day-to-day costs.

Lupin’s Key Markets Continue to Support Revenue Growth

Underlying business strength remains visible across major geographies.

• India sales grew 14.7% to Rs 2,383.6 crore.
• US sales increased 9.3% to Rs 3,020.2 crore.
• Other developed markets surged 45.7%.
• Emerging markets declined 3.5%.
• API sales rose 20.2%.

India, the US and developed markets drove the bulk of topline expansion. These regions offset softer performance in emerging markets and reinforced the company’s ability to grow sales even amid margin pressure.

Lupin continues to invest in its future, spending Rs 618.1 crore on R&D, or 7.9% of sales. Managing Director Nilesh Gupta expressed confidence in long-term growth prospects, citing portfolio strength, ongoing R&D and commercial investments, and disciplined execution.

The contrast between healthy business growth and current profitability pressure remains clear. The next challenge lies in sustaining revenue momentum while restoring margins and earnings growth.